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Abstract: Aberrant expression of mucins is associated with cancer 
development and metastasis. An overexpression of few mucins con-
tributes to oncogenesis by enhancing cancer cell growth and providing 
constitutive survival signals. This review focuses on the importance of 
mucins both in the normal bronchial epithelial cells and the malignant 
tumors of the lung and their contribution in the diagnosis and prognosis 
of lung cancer patients. During lung cancer progression, mucins either 
alone or through their interaction with many receptor tyrosine kinases 
mediate cell signals for growth and survival of cancer cells. Also, 
stage-specific expression of certain mucins, like MUC1, is associated 
with poor prognosis from lung cancer. Thus, mucins are emerging as 
attractive targets for developing novel therapeutic approaches for lung 
cancer. Several strategies targeting mucin expression and function are 
currently being investigated to control lung cancer progression.
Key Words: Lung cancer, Mucins, MUC1, MUC4, MUC5AC, 
MUC7, Mucin vaccines, L-BLP25, TG4010, Aptamer.
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Mucins are high molecular weight, heavily glycosylated proteins that are expressed in the epithelial cells of vari-
ous organs. The presence of a variable number of tandem repeats 
in the extracellular domain distinguishes mucins from other 
glycoproteins. The number of tandem repeats is unique to each 
mucin and contains several proline, threonine, and serine (PTS) 
residues, but is usually devoid of cysteine residues. This mucin 
domain/PTS region provides the acceptors for relatively short 
O-linked glycans (2–20 monosaccharides per chain).1 The PTS 
region forms the densely packed filamentous carbohydrate-rich 
moiety that determines most of the biophysical properties of 
mucins. Mucins are classified into two major groups: membrane-
bound mucins and the secretory mucins (Fig. 1). There are 11 
membrane bound mucins, namely, MUC1, MUC3A, MUC3B, 
MUC4, MUC12, MUC13, MUC15, MUC16, MUC17, MUC20 
and MUC21; and seven secreted mucins, MUC2, MUC5AC, 
MUC5B, MUC6, MUC7, MUC8, and MUC19.2 Mucins are 
expressed during embryonic stages of lung development and are 
involved in the normal development of the lung.
Several reports suggest that mucins are overexpressed in 
non–small-cell lung cancer (NSCLC) and can be used as suit-
able biomarkers for identifying and monitoring the progres-
sion of lung cancer.3–6 Under normal conditions, mucins serve 
as a protective barrier for epithelial cells of various organs 
including lung.7 Deregulation of membrane-bound and secre-
tory mucins is associated with cancer progression and metas-
tasis by altering various signaling pathways.8–10 Of the various 
mucins, membrane-bound mucin MUC1 and secretory mucin 
MUC5AC seem to be predominantly found in NSCLC and are 
correlated with disease progression.
Lung cancer is the most common cause of cancer-
related deaths in the United States.11 Mucins have not been 
extensively studied for their role in the pathogenesis of lung 
cancer. This may be due to the complexity of mucin biology 
and the existence of multiple mucins with differing func-
tions within the cell. However, as our knowledge of mucins 
in other diseases is increasing, the role of various mucins 
in lung cancer too will be understood better. This review 
addresses the current knowledge about the expressional sta-
tus and role of mucins in lung cancer cell, their significance 
as prognostic and diagnostic markers and their potential as 
therapeutic targets.
EXPRESSION AND FUNCTION OF MUCINS IN 
NORMAL LUNG EPITHELIUM
Mucins secreted by the goblet cells in the respiratory 
epithelium form the mucosal coat of the apical epithelium and 
thereby protect the airways and alveoli from insults such as dehy-
dration, pathogen invasions, and chemical agents.12 In a normal 
airway, expression of MUC1 is weak, and a diffuse signal is 
observed in the tracheobronchial and collecting duct epithelium. 
MUC1 expression is not observed in the submucosal glands and 
bronchioles.13 Weak MUC2 expression is observed in the entire 
respiratory epithelium; however, the basal pole of some goblet 
cells expresses MUC2 moderately.13 MUC2 is undetectable in 
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the bronchioles and alveolar epithelial cells.14 In contrast, most 
of the respiratory epithelial cells including the basal, ciliated, 
and goblet cells as well as the collecting ducts express MUC4.15 
Strong expression of MUC4 is found in the collecting ducts of the 
sub-mucosal glands and alveolar epithelial cells.14 Interestingly, 
MUC4 is one of the first mucins expressed in the early stages 
FIGURE 1.  Structure of membrane-bound and secretory type mucins and their domain. Schematic representation of the most 
differentially expressed membrane-bound (MUC1 and MUC4) and secretory mucins (MUC5AC) in lung cancer and their associ-
ated O-glycans: lung cancer is characterized by differential expression of MUC1 and de novo expression of MUC4 and MUC5AC. 
Domain structure of MUC1: The epitome of membrane-bound mucins, MUC1, is characterized by the presence of an N-terminal 
sequence, 20 tandem repeat domains (20–120 amino acid each), single self-cleavable sea-urchin sperm protein, enterokinase, 
and agrin (SEA) domain (two subunits of MUC1 are generated by auto-proteolysis at the SEA domain that, in turn, forms a stable 
noncovalent heterodimer), single spanning TM domain and 72 amino acid (aa) cytoplasmic tail (CT) that contains binding sites for 
various effector molecules including ERα, p53, GSK-3β, PKCδ, cSRC, and β-catenin. The MUC1 cytoplasmic tail is target of various 
oncogenic signaling pathways. Domain structure of MUC4: De novo-expressed transmembrane mucin MUC4 is putatively cleaved 
at Gly-Asp-Pro-His (GDPH) proteolytic site generating an extracellular subunit MUC4α and the membrane-tethered subunit 
MUC4β. MUC4α is characterized by a unique N-terminal sequence, three imperfect repeats, heavily O-glycosylated tandem repeat 
domain of 16 amino-acids, a cysteine-rich domain (CRD), a nidogen (NIDO) domain having similarity to the nidogen-epidermal 
growth factor (EGF) domain of ancestral nidogen proteins, eight invariant cysteine residues containing the adhesion-associated 
domain in MUC4 and other proteins (AMOP) domain. MUC4β is a growth factor-like subunit characterized by the presence of 
three EGF like domains, a vWD-domain having similarity to dimerization domains of the von Willebrand D (VWD) factor, a mem-
brane-spanning transmembrane domain and a short cytoplasmic tail of 32 amino acids. Domain structure of MUC5AC: MUC5AC, 
a differentially expressed gel-forming mucin, has N- and C-terminal domains with high similarity to cystein-rich domain that is 
involved in disulfide-linked multimer formation. It includes disulfide-rich D-domains (D1, D2, D’, and D3) at the N-terminus and 
D4, B, C, and CK (vWF-like domain) at the C-terminus. The central region is characterized by CRDs (n = 17, aa = 110 having 10 
cysteine residues). The first nine CRD are interspersed by threonine/serine/proline-rich domains (TSP) with no repetitive sequences, 
whereas Cys5 to Cys9 domains are interspersed with highly O-glycosylated TR domains (N = 4). Through its CRDs and CK domain, 
it forms disulfide-linked dimers and oligomers. Furthermore, its C-terminus has a GDPH autocatalytic proteolytic site.
21Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015 Mucins in Lung Cancer
of embryonic development in the lungs (as early as 6.5 week 
after gestation),13 and it is speculated to be involved in the dif-
ferentiation of all respiratory epithelial cells.13 After 12 weeks of 
gestation, MUC4 is observed in the small bronchi and bronchi-
oles of lungs (Table 1).13,15 Moderate expression of MUC5AC is 
initially observed at the 13th week of gestation in the epithelial 
buds of the segmental bronchi. MUC5AC is strongly expressed 
in the trachea and main bronchi, but no expression is seen in 
the bronchioles and smaller alveolar epithelial cells.14 MUC5AC 
is also expressed in the goblet cells of the surface epithelium 
and in the glandular ducts.14 MUC5B starts to appear after the 
13th week of gestation and a weak expression is observed in the 
bronchial epithelium, mucous cells of the sub-mucosal glands, 
and glandular ducts.13,15 MUC5B is not expressed in the bron-
chioles and alveolar epithelial cells, but is strongly expressed in 
the collecting ducts and mucous cells of sub-mucosal glands.16 
MUC7 transcript is detected only in the serous cells of some 
sub-mucosal glands.15 Other mucins such as MUC3 and MUC6 
are not expressed in the normal respiratory mucosa.15 In sum-
mary, mucins exhibit distinct spatiotemporal expression pattern 
in different regions of the respiratory epithelium and during lung 
development (Table 1).
MUCINS IN LUNG CANCER
MUC1
In normal epithelial cells, MUC1 expression is restricted 
to the luminal side of the cells.17 However, during progression of 
lung cancer, there is a loss of cell polarity with resulting MUC1 
expression over the entire cell surface.18 MUC1 expression has 
been classified into three types, high-grade polarized expres-
sion (HP), low-grade polarized expression (LP), and depolarized 
expression (DP). HP is defined as having polarized expression 
of MUC1 in greater than 50% tumor cells and less than 10% 
cells showing depolarized expression of MUC1. LP is less than 
50% of cells with polarized expression of MUC1 and less than 
10% of depolarized expression of MUC1, whereas DP is con-
sidered as depolarized MUC1 expression in greater than 10% of 
cancer cells.5,19 Based on this classification, HP of MUC1 was 
seen in well-differentiated adenocarcinoma, whereas depolarized 
expression of MUC1 correlated with increasing stage and lymph 
node metastasis.20,21 Depolarization of MUC1 expression extends 
from the apex and moves across the entire surface thereby pre-
venting cell–cell and cell–matrix interaction, thereby resulting 
in increased invasion into adjacent tissues. Differential polarized 
expression of MUC1 was also observed between primary and 
pulmonary metastatic tumors. HP and DP of MUC1 were signifi-
cantly higher in primary lung cancer tissues than in that of meta-
static lesions.5 Increased depolarized expression of MUC1 also 
correlated with progression of atypical adenomatous hyperplasia 
(AAH) and bronchioloalveolar carcinoma (BAC; adenocarci-
noma with lepidic pattern in the new International Association 
for the Study of Lung Cancer [IASLC] classification).3
The clinicopathological significance of MUC1 was ana-
lyzed in 126 patients with primary lung cancer and 147 patients 
with metastatic tumors in the lung. The (18)F-FDG uptake was 
higher in patients with depolarized expression (DP) as com-
pared with namely HP or LP. HP and DP pattern of MUC1 
was seen in a higher proportion of patients with primary lung 
tumors as compared with metastatic lesions but LP of MUC1 
was detected in a higher proportion of patients with metastatic 
lesions.5 The study suggested that depolarized expression of 
MUC1 was associated with poor prognosis. These findings sug-
gest that differential distribution of MUC1 plays a significant 
role in aggressiveness of lung cancer and metastasis.
MUC1 signaling and its role in aggressiveness of lung 
cancer cells
MUC1 overexpression induces several downstream sig-
naling pathways that are closely associated with poor clinical 
TABLE 1.  Mucins Expression in Normal Bronchial Cells and Carcinomas
Mucins Expression in Normal Respiratory Tract Expression in Preinvasive and Invasive Lesions
MUC1 Trachea bronchial epithelium, collecting ducts, submucosal 
gland and bronchioles13
Preinvasive:54
All preinvasive lesions: 77% (34 of 44)
Squamous dysplasia: 83.3% (20 of 24)
Bronchiolar columnar cell dysplasia: 83.3% (5 of 6)
Basal cell dysplasia: 66.6% (4 of 6)
Bronchial epithelial dysplasia with transitional differentiation: 66.6% (2 of 3)
Columnar cell dysplasia: 66.6% (4 of 6)
Invasive:54
Squamous component: 96.7% (30 of 31)
Adenocarcinoma components: 87% (27 of 31)
MUC4 Goblet cells, collecting duct, and alveolar epithelial cells13,15 Adenocarcinomas: 81% (151 of 187)6
Squamous cell carcinomas: 78% (69 of 88)
Adenosquamous carcinomas: 75% (6 of 8)
Large cell carcinomas: 55% (33 of 60)
MUC2 Respiratory epithelium, goblet cells13 No data
MUC5AC Surface epithelium of goblet cells, trachea, and main bronchi13,14 Stage I NSCLC: 16 of 61 (26.2%)74
MUC5B Bronchioles and alveolar epithelial cells, collecting duct and 
submucosal gland13,15
No data
MUC7 Serous cells of submucosal gland.13,15 No data
BCCD, bronchiolar columnar cell dysplasia; BCD, basal cell dysplasia; BEDT, bronchial epithelial dysplasia with transitional differentiation; CCD, columnar cell dysplasia; 
NSCLC, non–small-cell lung cancer.
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outcomes.22 Overexpression of MUC1 favors angiogenesis 
by upregulating vascular endothelial growth factor (VEGF) 
expression through activation of the Akt and ERK signaling 
pathways. Giatromanolaki et al.23 demonstrated that highly vas-
cularized NSCLC tumors had high MUC1 expression, and this 
appeared to correlate with VEGF expression. MUC1 is also 
involved in the inactivation of integrin-mediated cell-to-matrix 
adhesion and E-cadherin mediated cell-to-cell adhesion.24 MUC1 
knockdown led to sensitization of NSCLC cell lines to cisplatin 
treatment and elevated apoptosis due to reduced Bcl-XL activity.25
MUC1 has been shown to interact with EGFR and 
β-catenin through its cytoplasmic domain and promote 
cancer cell proliferation.26 MUC1 cytoplasmic domain con-
tains 72 amino acids; a 15 amino acid sequence is respon-
sible for interaction with EGFR (YEKV) and β catenin 
(SAGNGGSSLS).27 Bitler et al.28 synthesized a MUC1 
inhibitory peptide to block these interactions along protein 
transduction domain PTD4 for enhancing the cellular uptake. 
MUC1 inhibition in lung cancer cells led to decreased pro-
liferation by affecting transcription of the estradiol-activated 
reporter genes, endogenous cyclin D1, and nuclear respira-
tory factor-1.29 MUC1 C-terminal (MUC1-C) subunit forms 
a complex with EGFR by interacting with Galectin-3.30 In 
addition, the MUC1-C acts as a substrate for c-Src phos-
phorylation in lung cancer cells.27 Recently, MUC1-C was 
reported to be aberrantly expressed in NSCLC and through 
its association with p85 subunit of PI3K was found to 
enhance the Akt signaling pathway.31
MUC1 undergoes oligomerization through its Cys-
Gln-Cys (CQC) motif present on its cytoplasmic domain and 
promotes cancer cell proliferation. The MUC1 inhibitor 
(GO-201) inhibits MUC1 oligomerization by binding to 
the cytoplasmic domain and reduces MUC1-mediated cell 
proliferation (Fig. 2).32 In addition, other MUC1-specific 
FIGURE 2.  Differential signaling of mucins in lung cancer pathogenesis. Overexpression of MUC1 activates various signaling 
pathways for lung cancer cell proliferation through PI3K and Akt activity, MUC1 also participates in angiogenesis through regu-
lation VEGF expression. MUC1 and EGFR signaling also promote lung cancer cell proliferation through Src signaling pathways. 
Similarly, secretory mucin MUC5AC promotes lung cancer cell proliferation by alterating Ras signaling pathways and cytokines. 
Several inhibitors are available to inhibit the lung cancer cell proliferation either by directly targeting MUC1 by L-BLP25, G0203, 
or by Mucins downstream target such mTor and ERK1/2 and Akt. EGF, epidermal growth factor; mTOR, mammalian target of 
rapamycin; ER-α and β, estrogen receptor α and β; VEGF, vascular endothelial growth factor; SRC-v-src, aviansarcoma.
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inhibitors such as GO-202 and 203 were also associated with 
an impaired proliferation of lung adenocarcinoma cells.29 
Blocking the oligomerization of MUC1-C by G0-203 inhib-
ited NSCLC cell growth and survival by preventing the inter-
action between MUC1-C and PI3K-p85. This resulted in the 
inhibition of Akt phosphorylation and mammalian target of 
rapamycin activity (Fig. 2).32
MUC1 gene can be regulated by various signaling 
molecules and transcription factors in the airway epithelial 
cells and lung cancer cells. STAT3 is highly overexpressed 
in NSCLC and its knockdown significantly downregulates 
MUC1 expression, indicating that STAT3 regulates MUC1 
gene expression in lung cancer cells (Fig. 3).8 Mikami et 
al.25 showed that hypoxia induced MUC1 expression in lung 
FIGURE 3.  Regulation of mucin genes through various signaling pathways in lung cancer cells: The transcription factor STAT3 
regulates MUC1 gene expression in lung cancer cells under hypoxia condition through HIF1-α.8 Further MUC1gene is also 
regulated by microRNA149 in lung cancer cells.34 TNF-α–converting enzyme (TACE) also regulates both MUC1 and MUC5AC in 
lung cancer cells. For MUC1 gene expression, neutrophil elastase may activate Protein kinase C δ for expression of dual oxidase 
1 (Duox1) that leads to reactive oxygen species production for TACE activation. Then TACE induced MUC1 gene expression 
through TNF-α/TNF-α-Receptor/ERK1/2/SP-1 transcription factor (Pathway A). For MUC5AC gene expression, chemokine (C–C 
motif) ligand (CCL20) binds with GPCR complex through EGFR activation. Then TACE induce the MUC5AC gene expression 
through ERK1/2 signaling (Pathway B). Notch1 upregulates EGFR expression that leads to MUC5AC gene expression through 
ERK signaling.44 (Pathway C.) In addition, MUC5AC gene can also be regulated by microRNA-378 in lung cancer and its expres-
sion positively correlates with MUC5AC gene expression.49 MUC2 and MUC6 genes may be regulated by CDX transcription 
factors in lung cancer cells. Collectively EGFR and its downstream signaling molecule ERK1/2 are necessary for mucin gene 
expression in lung cancer cells. STAT3, signal transducer and activator of transcription 3; EGFR, epidermal growth factor recep-
tor 1; TGF-α, transforming growth factor-α; ERK1/2, extracellular signal-regulated protein kinases 1 and 2; HIF1α, hypoxia-
inducible factor 1-α; CCL20-Chemokine (C–C motif) ligand 20; GPCR, G protein-coupled receptors; TACE-TGF-α, tumor 
necrosis factor-α–converting enzyme, CDX1 and 2, caudal type homeobox 1&2. Similarly, MUC2 and MUC6 genes can be 
regulated by CDX molecules as well as SP-1.
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adenocarcinoma cells by means of HIF-1α, and was partially 
responsible for lung cancer progression. Neutrophil elastase 
regulates MUC1 mucin gene expression through Sp-1 tran-
scription factor in lung cancer cells. Specific binding of Sp-1 
on the MUC1 gene promoter between -99/-90 induced gene 
transcription (Fig. 3).33 Similarly, the same group has eluci-
dated the detailed signaling mechanism of Sp-1-mediated 
MUC1 gene expression, e.g., neutrophil elastase can acti-
vate protein kinase δ and dual oxidase 1 (Duox1) that leads 
to reactive oxygen species production for TNFα-converting 
enzyme (TACE). TACE, in turn, activates TNFα and its recep-
tor TNFR and results in MUC1 gene expression through 
MEK1/2, ERK1/2, and Sp-1 (Fig. 3). This study suggests that 
the anti-inflammatory role of MUC1 is controlled by inflam-
matory mediators, such as neutrophil elastase and TNFα.33 In 
addition, microRNA 149 has shown to repress MUC1 expres-
sion in lung adenocarcinoma.34 Thus, MUC1 is overexpressed 
in lung carcinoma and its expression is tightly regulated by a 
number of inflammatory regulators (Fig. 3).
MUC4
MUC4 is aberrantly overexpressed in many tumors 
including lung carcinoma.35 Membrane-bound MUC4 is 
widely expressed in NSCLC, but its expression varies between 
different histologic subtypes. Adenocarcinoma cells express 
more MUC4 than squamous cell carcinoma and large cell car-
cinoma cells.6 MUC4 expression was detected in the pleural 
infiltration zone and has been shown to be required for lung 
adenocarcinoma development.36
Karg et al.37 reported a significant association of MUC4 
expression with HER2/ERBB2 that resulted in apoptosis and 
differentiation rather than lung cancer cell proliferation. In con-
trast, other studies have demonstrated that MUC4 expression 
was unrelated to MUC1, HER2, and p27 expression, thereby 
suggesting that MUC4 can be used as an independent prognostic 
marker for lung adenocarcinoma.38 Recently, we demonstrated 
that MUC4 expression was associated with decreased prolifera-
tion, motility and invasion of lung cancer cells by attenuating 
the activation of Akt, Cyclin D1, and Cyclin E39 (Fig. 2).
In lungs, MUC4 gene expression is controlled by IL-9 
in a time- and dose-dependent manner; Jak3 appears to be 
involved in IL9-mediated MUC4 gene expression (Fig. 3).40 
MUC4 seems to also be controlled by an epigenetic mecha-
nism. When the DNA methylation status of 94 CpG sites from 
−3622 to +29 was analyzed using a MassARRAY analysis, the 
MUC4 expressing H292 lung cancer cell line had low meth-
ylation levels (near the transcriptional start site) and hypo-
methylation at the CpG sites 108 to 112 was associated with 
MUC4 expression.41 Similarly, when non-MUC4 expressing 
A427 lung cancer cells were treated with hypomethylating 
agents, 5-aza-2′-deoxycytidine and trichostatin A, there was 
an increase in the MUC4 mRNA expression suggesting that 
methylation status may regulate MUC4 expression.
Secretory mucins MUC5AC, MUC5B, MUC2, MUC6, 
and MUC7
Secretory mucins protect tumor cells from exog-
enous cytotoxicity or genotoxicity and contribute to their 
aggressiveness. Mucinous adenocarcinoma, a more aggres-
sive subtype of lung adenocarcinoma, has a high expression 
of MUC2, MUC5AC, and MUC6. The aggressiveness of the 
tumor may be dependent on the mucins it secretes.42
Of all the mucins in airway epithelium, the regulation 
of MUC5AC is most well studied. Human MUC5AC expres-
sion is regulated by chemokine (C–C motif) ligand (CCL20)/
GPCR complex by EGFR activation by means of metallo-
protease TACE.43 A recent study has elucidated two differ-
ent mechanisms of EGFR-mediated MUC5AC synthesis and 
secretion in H292 lung cancer cells: (1) EGFR phosphory-
lation upon binding to TGF-α results in the production of 
MUC5AC and CCL20 by means of ERK activation, and (2) 
EGFR phosphorylation is directly activated by TACE which 
cleaves the proligands specific for EGFR43 (Fig. 3).
In atypical adenomatous hyperplasia (AAH) and BAC 
with mixed subtypes (classified as “adenocarcinoma, predom-
inantly invasive with some nonmucinous lepidic component” 
in the 2011 IASLC/ATS/ERS classification of adenocarci-
noma), cells express high levels of secretory mucins such as 
MUC2, MUC5AC, and MUC6. The expression of MUC2 and 
MUC5AC are controlled by epidermal growth factor fam-
ily and mitogen-activated protein kinase (MAPK) cascade.14 
MUC2 expression was also associated with wild type p53, 
but not mutant p53. Treatment of H292 lung cancer cells with 
EGF and TNF-α resulted in increased expression of MUC2 
and MUC5AC but there was no change in MUC5B and 
MUC6 expression.14 Upregulated MUC2 and MUC5AC bind 
with EGFR and activate the Ras/Raf pathway, which in turn 
leads to cell proliferation.
Notch-1 regulates MUC5AC synthesis in NCI-H292 
human lung carcinoma cells through the ERK pathway 
(Fig. 3).44 MUC5AC gene expression is strongly repressed by 
dexamethasone treatment, possibly through the glucocorti-
coid receptor and two glucocorticoid response elements in the 
MUC5AC promoter.45,46 The extracellular matrix also regu-
lates MUC5AC production in H292 human lung cancer cells. 
When H292 cells are grown on type-IV collagen, MUC5AC 
production is downregulated through an integrin/Src-
dependent pathway.47 Conversely, another study has shown 
that laminin upregulates MUC5AC production by means of 
an Src-dependent pathway.47 Bai et al.48 have reported that 
leukotriene D4 regulates the expression of both MUC2 and 
MUC5AC in NCI-H292 cells through the transcription fac-
tor SP-1, which is required for efficient transcription. Also, 
microRNA-378 positively correlates with MUC5AC expres-
sion in lung cancer cells and it results in increased prolifera-
tion and migration (Fig. 3).49
CDX is an intestine-specific homeobox gene that also 
regulates mucin gene expression, particularly MUC2 and 
MUC6.50 Human lung adenocarcinoma xenografts express 
more MUC6 than squamous cell carcinoma xenografts, and 
its expression correlates with transcription factors CDX1 and 
CDX2.50 Similarly, Rossi et al. have also reported that CDX2 
regulates MUC2 gene transcription in lung cancer.51 MUC7 
expression in lung and trachea has been shown to be signifi-
cantly upregulated in response to cigarette smoke extract in 
lung cancer cells.52 Similarly, combined treatment of cigarette 
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smoke extract and lipopolysaccharide resulted in synergistic 
upregulation of MUC7 transcripts in NSCLC cell lines.52
MUCIN EXPRESSION: CLINICOPATHOLOGICAL 
CORRELATION
MUC1
Situ et al. observed that MUC1 was more frequently 
expressed in adenocarcinoma (86.3%) than squamous cell 
carcinoma (39.1%) and other subtypes of NSCLC (74.1%). 
In this study, MUC1 was an independent prognostic factor 
for overall survival and disease-free survival in patients with 
stage IB NSCLC.53 Demirag et al.54 have demonstrated that 
MUC1 is detected in adenosquamous carcinoma of the lung 
and strongly associated with disease progression. MUC1 is 
differentially expressed in smoke-exposed lung and lung 
cancer tissue.55,56 Khodarev et al.57 have identified 35 genes, 
induced by MUC1, that may be involved in lung and breast 
tumorigenesis. Taking this study further, MacDermed et al. 
identified MUC1-associated proliferation signature. This 
study demonstrated that MUC1-cytoplasmic domain (MUC1-
CD)-associated genes are involved in DNA damage response 
and tumor formation.58
Serum KL-6 glycoprotein classified as MUC1 is a sensi-
tive biomarker for interstitial lung diseases.59 Shields60 observed 
a positive association between circulating levels of KL-6 and 
subsequent risk of lung cancer. MUC1 mRNA expression was 
observed in the peripheral blood of 80% (48 of 60) of NSCLC 
patients compared with 65% (13 of 20) of healthy controls. 
Furthermore, aberrant MUC1 expression on the stroma-facing 
cell surface or diffuse distribution in the cytoplasm (cytoplasmic 
pattern) correlated with a poor prognosis from lung cancer.61
MUC4
Multiple studies have shown that MUC4 expression sig-
nificantly correlates with the histological type of lung carci-
noma.4,6,36,37,62 Increased expression of MUC4 was observed 
in squamous cell carcinoma, particularly central areas of 
cancer cell nests and in squamous pearls, but was absent in 
less differentiated peripheral tumor cells.6 MUC4 mRNA 
overexpression was also observed in lung cancer carcinoma 
cells compared with normal epithelium.4 In an immunohis-
tochemical and reverse transcription-polymerase chain reac-
tion analysis of 29 tumor samples, 67% expressed MUC4 
protein and 72% of samples had MUC4 mRNA overexpres-
sion.4 Lower disease-free interval was observed in patients 
expressing high levels of MUC4 (≥25% of neoplastic cells 
stained).38 A recent study demonstrated that MUC4 deficient 
lung cancer cells induced epithelial to mesenchymal transition 
process; decreased MUC4 expression was found in patients 
who had adenocarcinoma involving lymph nodes.63 Similarly, 
we found that elevated expression of MUC4 was correlated 
with decreased proliferative capacity of lung cancer cells.39 
These contrasting observations suggest that the actual role of 
MUC4 in lung cancer is unclear.
MUC4 expression was observed by immunohistochem-
istry in most subtypes of NSCLC; adenocarcinomas 81% (151 
of 187), 78% (69 of 88) of squamous cell carcinoma, 75% (6 
of 8) adenosquamous carcinoma, and 55% (33 of 60) of large 
cell carcinoma.6 Furthermore, MUC4 expression distinguished 
lung adenocarcinoma from malignant mesothelioma.36
A study showed that patients with stage I (138 patients) 
and II lung adenocarcinoma (17 patients) expressed significantly 
high levels of MUC4. Increased expression of MUC4 correlated 
with shorter disease-free interval and decreased overall survival 
in early stage lung adenocarcinoma.38 However, two other stud-
ies have shown that MUC4 expression is associated with bet-
ter lung cancer outcomes.6,39 Our recent studies indicated that 
MUC4 expression in the primary tumor was greater than that 
in corresponding lymph node metastases.39 These differences 
could be attributed to stages, types of patients, number of sam-
ples analyzed and methods utilized for the analysis of MUC4.
Other mucins
MUC5AC and MUC6 seem to be expressed only in 
mucin-filled glandular and cystic lung adenocarcinoma.64 
MUC5AC expression has been shown to be higher in adeno-
carcinomas compared with squamous cell carcinomas.15 Yu et 
al. observed MUC5AC overexpression in 26.2% (16 of 61) of 
stage I/II NSCLC patients and noted a significant association 
between MUC5AC expression and gender, adenocarcinoma 
histology, and a nonsmoking history. MUC5AC expression 
appears to increase the risk of distant metastasis and decrease 
overall survival from lung cancer.65
MUC5AC expression has been shown to increase sig-
nificantly during the progression from AAH through BAC 
(classified as “adenocarcinoma in situ” in the 2011 IASLC/
ATS/ERS classification of adenocarcinoma) to adenocarci-
noma and alterations in MUC5AC expression were associated 
with dedifferentiation of bronchial epithelium.66 MUC5B and 
MUC5AC overexpressing tumors tended to relapse or metas-
tasize postoperatively more often, compared with nonexpress-
ing tumors.65
In summary, there are increasing data regarding the 
clinical utility of various mucins as potential biomarkers in 
lung adenocarcinoma. However, based on the available evi-
dence, no definite conclusions can be drawn about their utility 
at this time and more studies evaluating the clinical utility are 
required at this time.
MUCINS AS THERAPEUTIC TARGETS
Several approaches targeting MUC1 are currently in 
clinical trials for NSCLC. MUC1 has T-cell-specific anti-
genic epitopes that bind to HLA class I molecules. MUC1 
has been explored as a target for immunotherapy using 
immunodominant peptides from variable number of tandem 
repeat region region.67 L-BLP25 (tecemotide) is an liposomal 
vaccine targeting MUC168, and has been shown to be effec-
tive and safe in NSCLC.23 In one study, 16 of 78 patients 
had a specific T-cell proliferative response against MUC1 
induced by the L-BLP25 vaccine.69 MUC1 (60mer peptide 
from the tandem-repeat sequence) immunization generated 
T-lymphocyte-mediated cytotoxicity specific to MUC1,70 an 
activity independent of the MHC-I complex.71 A recent phase 
IIb trial randomized stage IIIb/IV NSCLC patients for treat-
ment with either L-BLP25 or best supportive care, this study 
demonstrated that although there was no improvement in 
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overall survival in the entire cohort, the subgroup of patients 
with stage IIIb disease had a statistically significant (30.6 ver-
sus 13.3 months; HR, 0.548) improvement in median overall 
survival.69 Similar studies also reported that tecemotide pro-
longed survival in East Asian patients with stage III NSCLC.72 
Unfortunately, two studies, a randomized placebo-controlled 
phase III study and a phase II study being conducted to 
identify a possible role for tecemotide in locally advanced 
NSCLC after completion of chemoradiation (NCT02049151 
and NCT00828009) were recently discontinued by the spon-
sor, because of concerns regarding a lack of efficacy.
TG4010 is another MUC1-targeted vaccine based on 
recombinant attenuated strain of vaccina virus expressing 
MUC1 and IL-2.73 A phase II study using a combination of 
TG4010 with cisplatin and vinorelbine resulted in improved 
outcomes in patients receiving first-line chemotherapy. The 
response rate in this study was 29.5%, median survival was 
12.7 months and 1-year survival was 53%.73 A randomized 
study evaluating the combination of TG4010 with platinum-
based chemotherapy is currently underway.
MUC1-specific aptamer is made by pDNA/polyethylen-
imine/aptamer (pDNA/PEI/aptamer) complexes. The pDNA/
PEI/MUC1 aptamer complexes was designed for tumor-
specific gene delivery tissue.74 Under-glycosylated forms of 
MUC1 in tumor cells can be used for developing therapeutic 
vaccine strategies and biomarkers for prognosis.75
CONCLUSION AND PERSPECTIVES
Although mucins have not been well studied in lung 
cancer, they seem to play an important role in lung car-
cinogenesis. Due to their specific expression pattern and 
functional involvement in lung cancer, mucins may provide 
important diagnostic and therapeutic targets. It is possible 
that the interactions between various mucins may add another 
level of complexity in our understanding of their role in lung 
carcinogenesis.
MUC1-targeted therapies are currently in clinical tri-
als against lung cancer. Depolarized expression of MUC1 is 
associated with aggressiveness of lung cancer, and MUC1-
associated genes have been identified as possible prognostic 
and diagnostic markers in lung cancer. MUC1-associated pro-
liferation signature may have utility for diagnosis and treat-
ment of lung cancer. MUC5AC is overexpressed in lung cancer 
and it is associated with a poor prognosis. Although there are 
no current data, the role of the secretory mucin MUC5AC as 
a prognostic biomarker for lung cancer is worth investigating.
More detailed studies are also needed to elucidate the 
role of mucins in lung cancers with different mutational back-
ground such as Kras, EGFR, and BRAF. Further studies are 
required to identify specific mucins that can serve as diagnos-
tic or prognostic markers during the initiation and progression 
of lung cancer and to gain a better understanding of the unique 
role for each mucin and their interplay with each other during 
lung carcinogenesis.
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